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Background. Fibrinolysis contributes to coagulopathy after major trauma and surgery. We
hypothesized that progressive haemodilution is responsible, at least in part, for increased fibri-
nolytic tendency of blood clot.
Methods. The study was performed in two parts. First, whole blood (WB) samples collected
from six healthy, consented volunteers were diluted in vitro with either saline or fresh-frozen
plasma (FFP) to 40% and 15% of baseline. We quantified factor levels related to coagulation and
fibrinolysis, and measured endogenous thrombin generation in undiluted control plasma
samples and in samples diluted with saline or FFP. Additionally, thromboelastometry was used
to assess susceptibility to fibrinolysis after adding tissue plasminogen activator in undiluted WB
samples and in samples diluted with saline before and after substitution of fibrinogen or FFP.
Secondly, as a model of in vivo haemodilution, we evaluated the same parameters before and
after operation in nine consented patients undergoing off-pump coronary artery bypass surgery.
Results. The dilution with saline caused dose-dependent decreases in plasma levels of coagu-
lation and antifibrinolytic factors, and in thrombin generation. In FFP-supplemented samples,
factor levels and thrombin generation were maintained within normal ranges. Fibrinolytic ten-
dency was significantly higher after haemodilution with saline independent of fibrinogen substi-
tution compared with FFP. Similarly, increased tendency for fibrinolysis was also observed in the
in vivo haemodilution.
Conclusions. We demonstrated in vitro and in vivo that progressive haemodilution decreases
endogenous antifibrinolytic proteins including a2-antiplasmin and thrombin-activatable fibrinoly-
sis inhibitor, resulting in increased fibrinolytic tendency. Therefore, early fluid replacement
therapy with FFP might be advantageous after massive haemorrhage.
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Major trauma and surgery induce various degrees of vas-
cular injury and exsanguination. In the case of massive
blood loss requiring infusion of large amounts of i.v.
fluids, coagulation factors are reduced to 30% of normal
levels after loss of 1 blood volume, and to 15% after loss
of 2 blood volumes.1 2 The loss of multiple procoagulant
factors is considered significant when prothrombin time
(PT) is prolonged over 1.5 times of normal.3 Although the
diagnostic value of PT to predict bleeding is questionable,4
fresh-frozen plasma (FFP) is frequently transfused in view
of prolonged PT and haemorrhage as per the current
guidelines.5 6 However, there is a paucity of data on the
regulation of fibrinolytic pathway and the role of FFP, if
any, in major haemodilution. We have previously
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demonstrated in vitro that clot resistance against tissue
plasminogen activator (tPA)-induced fibrinolysis decreases
after haemodilution.7 8 Therefore, we speculated that fluid
replacement using the crystalloid solution confers pro-
fibrinolytic effects by diluting endogenous antifibrinolytic
elements such as plasminogen activator inhibitor-1
(PAI-1), a2-antiplasmin, thrombin-activatable fibrinolysis
inhibitor (TAFI), and factor XIII (FXIII). Because FFP
contains all the endogenous antifibrinolytic elements in
plasma, it is plausible that clot stability against fibrinolysis
would be better maintained if FFP were given early in
massive traumatic haemorrhage.9 10 Potential haemostatic
mechanisms conferred by FFP have not been fully evalu-
ated, whereas immunological and non-immunological
complications of FFP transfusion have become obvious
concerns.6 11 12 We hypothesized that antifibrinolytic
activity of FFP could be demonstrated by comparing
whole blood (WB) haemodilution by normal saline vs
FFP. In the first part of this study, levels of antifibrinolytic
factors, thrombin generation, and thromboelastometric
measurements of clot stability against tPA were compared
after in vitro haemodilution (to about 40% and 15% of
baseline values by normal saline and FFP). Similarly, in
the second part of the study, increased fibrinolytic ten-
dency of WB clot after moderate haemodilution was eval-
uated in patients undergoing off-pump coronary artery
bypass (OPCAB) surgery in which antifibrinolytic therapy
is not routinely implemented.
Methods
After institutional approval and informed written consent,
blood samples were collected into 5 ml Vacutainer tubes
(Beckton-Dickinson, Franklin Lakes, NJ, USA) containing
sodium citrate 3.2% (0.5 ml) from six healthy volunteers
(three females and three males, age between 24 and 63 yr)
who had not received any drugs in the preceding 2 weeks
and had no history of coagulopathy. In addition, pre- and
postoperative blood samples from 10 patients undergoing
OPCAB surgery involving more than three distal anasto-
moses were collected after informed written consent. All
samples were obtained before heparin administration and
after heparin reversal by protamine but before any other
haemostatic intervention. OPCAB patients were chosen
because dilutional effects are often present after surgery,
but antifibrinolytics are not routinely used. Transfusion
practice during OPCAB surgery was guided by the
anaesthetist in charge and was not influenced by the study.
One patient was referred to surgery with the use of cardio-
pulmonary bypass, and therefore was excluded, leaving
nine patients for analyses (four females and five males,
age between 50 and 79 yr).
During the experiments, all blood samples, diluted and
undiluted, were either used immediately or centrifuged
at 2000g for 20 min (room temperature) to obtain
platelet-poor plasma (PPP) which was stored at 2808C
until analysis. For the in vitro model of haemodilution,
WB was diluted 1:1 and 1:3 v/v with normal saline or
allogeneic type-matched FFP, and haematocrit was
restored to 23–25% by adding allogeneic type-matched
RBC concentrate (haematocrit 52–63%). This dilution
model has been described previously7 and led to a total
dilution of coagulation factors and platelets to about 2:5
(40%) and 1:6 (15–20%) of baseline, respectively.
Fibrinogen has been shown to be protective against fibri-
nolysis.7 Therefore, in WB samples diluted to 15% of
baseline with saline, fibrinogen (Haemocomplettanw P;
CSL Behring, Marburg, Germany) was substituted at a
concentration of 2.7 g litre21 which approximates the con-
centration of fibrinogen in FFP. These samples were used
only for thromboelastometric measurements.
Laboratory measurements
We determined the following coagulation and antifibrino-
lytic markers and factors in PPP samples at baseline, and
after dilution to 40% and 15% of baseline in the in vitro
haemodilution model in healthy volunteers, and in pre-
and postoperative samples from OPCAB patients: PT,
international normalized ratio (INR), activated partial
thromboplastin time (aPTT), fibrinogen, antithrombin,
prothrombin (factor II), plasminogen, a2-antiplasmin, and
TAFI. Fibrinogen concentrations were determined using a
modified Clauss method. Plasma prothrombin activity was
determined using the one-stage clotting assay in factor II
deficient plasma according to PT. Plasma AT, plasmino-
gen, and a2-antiplasmin activity were determined using a
chromogenic method. These clotting and activity assays
were performed on the STA Compactw analyzer
(Diagnostica Stago, Parsippany, NJ, USA) using manufac-
turer’s kits and direction. TAFI antigen was determined
with an ELISA kit (Asserchromw TAFI, Diagnostica
Stago). Haemoglobin, haematocrit, and platelet count were
measured by Coulter AcT Series Analyzer (Coulter
Corporation, Miami, FL, USA).
Thrombin generation
The calibrated automated thrombin generation system
(ThrombinoscopeTM, Synapse BV, Maastricht, The
Netherlands) was used to estimate the amount of thrombin
generation based on the hydrolysis of a fluorogenic
peptide by thrombin. Lag time, peak thrombin level, and
endogenous thrombin potential were calculated as pre-
viously described by Hemker and colleagues.13 For throm-
bin generation experiments, we used PPP samples at
baseline and after dilution to 40% and 15% with either
saline or FFP in the in vitro model and pre- and postopera-
tive PPP samples from patients undergoing OPCAB
surgery. Recalcified PPP samples were run in duplicate for
thrombin generation triggered by 5 pM of relipidated
tissue factor.
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Thromboelastometric measurements
Thromboelastometry (ROTEMTM; Pentapharm, Munich,
Germany) measures the viscoelastic development from
thrombin-mediated fibrin polymerization and platelet acti-
vation. Thromboelastometry is characterized by specific
variables described earlier.7 Using this technique, we col-
lected the following parameters (Fig. 1): (i) coagulation
time (CT; in seconds), which corresponds to the reaction
time until clot formation; (ii) angle (a; in degrees), which
reflects the rate of fibrin polymerization; (iii) maximal clot
firmness (MCF; in millimetres), which refers to the
maximal amplitude of the tracing and reflects the tensile
strength of thrombus; (iv) lysis onset time (LOT; in
seconds) defined as the time needed for clot firmness to
decrease by 15% of MCF; and (v) lysis time (LT; in
seconds) defined as the time needed for clot firmness to
decrease by 90% of MCF. CT, angle, and MCF were
obtained in the absence of tPA, whereas LOT and LT were
evaluated in the presence of tPA.
The measurements in the blood samples from the same
volunteer or patient were conducted simultaneously using
three ROTEMTM analysers. All measurements were
repeated twice at 378C using 300 ml of diluted or
undiluted WB after recalcification with 20 ml of 0.2 M
CaCl2 and activation with 10 ml of tissue factor
(EXTEMw; Pentapharm) in the absence and presence of
tPA (Alteplasew; Genentech, South San Francisco, CA,
USA) at a concentration of 0.15 mg ml21.7 In OPCAB
patients, we additionally conducted the pre- and postopera-
tive analyses in the presence of cytochalasin D
(FIBTEMw; Pentapharm).
Statistics
All experiments had n6 per condition, as this number of
experiments is typically required to obtain a b0.8 and an
a0.05 for most thromboelastometric variables as demon-
strated in previous in vitro investigations.7 Data are
expressed as mean (SD) or range where appropriate after
testing by the Kolmogorov–Smirnov statistics for normal
distribution. Data in the in vitro model of dilution were
analysed using one-way analysis of variance (ANOVA) fol-
lowed by Bonferroni’s post hoc test. Data in the
patient model of dilution were compared by paired t-test.
A P-value of ,0.05 was considered significant. All ana-
lyses were performed using SPSSw Version 16.0 (SPSS
Inc., Chicago, IL, USA).
Results
Laboratory measurement
Table 1 shows blood cell counts and values for PT, INR,
aPTT, fibrinogen concentration, and prothrombin, antith-
rombin, plasminogen, a2-antiplasmin, and TAFI activity in
the in vitro model of dilution. After dilution to 40% and
15% of baseline with saline, all clotting parameters
decreased. Accordingly, PT and aPTT were prolonged to
about 1.7- to 1.8-fold of baseline after dilution to 40% and
to about 3- to 3.5-fold after dilution to 15%. In contrast,
after dilution to 40% and 15% with FFP, all clotting par-
ameters remained within normal range and were not
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Fig 1 Thromboelastometric parameters: CT, angle, MCF, LOT, and LT
are depicted. For more explanation see text.
Table 1 In vitro dilution model in healthy volunteers. Data are mean (SD); per cent change relative to baseline value. Values for haemoglobin, haematocrit, and
platelet count were identical for the dilution with saline and FFP. P-values were obtained by ANOVA followed by Bonferroni’s post hoc test. *P,0.05 vs baseline.
FFP, fresh-frozen plasma; PT, prothrombin time; INR, international normalized ratio; aPTT, activated partial thromboplastin time; TAFI, tissue-activatable
fibrinolysis inhibitor
Baseline Dilution to 40% of baseline Dilution to 15% of baseline
With saline With FFP With saline With FFP
Haemoglobin (g litre21) 157 (5) 91 (7); 242%* 89 (8); 243%*
Haematocrit (%) 40.4 (1.9) 23.8 (1.9); 241%* 23.8 (2.1); 241%*
Platelet (109 litre21) 205 (31) 87 (17); 258%* 34 (5); 283%*
PT (s) 11.8 (0.8) 21.5 (2.6); þ82%* 12.4 (0.5); þ5% 42.6 (6.2); þ261%* 12.8 (0.4); þ8%
INR 0.84 (0.07) 1.79 (0.26); þ113%* 0.90 (0.04); þ7% 3.94 (0.70); þ369%* 0.93 (0.03); þ11%
aPTT (s) 31.0 (4.5) 52.4 (11.5); þ69%* 34.2 (2.7); þ10% 90.0 (17.4); þ190%* 36.7 (2.8); þ18%
Fibrinogen (g litre21) 3.2 (0.5) 1.5 (0.2); 264%* 3.0 (0.2); 28% 0.5 (0.1); 284%* 2.8 (0.2); 212%
Prothrombin (%) 109 (10) 47 (5); 257%* 105 (8); 24% 19 (3); 283%* 98 (6); 210%
Antithrombin (%) 123 (10) 50 (7); 259%* 114 (2); 27% 28 (3); 277%* 100 (6); 219%*
Plasminogen (%) 98 (6) 42 (4); 257%* 90 (6); 28% 26 (1); 274%* 86 (4); 212%*
a2-Antiplasmin (%) 95 (13) 38 (5); 258%* 89 (4); 26% 17 (2); 280%* 84 (4); 212%*
TAFI (mg ml21) 9.7 (1.3) 3.7 (0.3); 262%* 9.5 (0.6); 22% 2.0 (0.1); 279%* 8.7 (1.0); 210%
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different from baseline (P.0.05) except that antithrombin
and plasminogen levels were slightly lower than at base-
line. Similar trends were demonstrated in the in vivo
model of haemodilution, presented in Table 2. Blood
samples after OPCAB surgery were diluted to about 60%
of baseline values by administration of saline (1800–4000
ml) and albumin 5% (500–1000 ml). Haemoglobin, plate-
let count, fibrinogen, and activities of prothrombin, antith-
rombin, and all antifibrinolytic factors were significantly
decreased, whereas PT and aPTT values increased by
about 1.3- to 1.4-fold relative to baseline values (all
P0.010).
Thrombin generation
In the in vitro model of dilution, lag time was 2.6 (0.5)
min at baseline and did not change significantly after pro-
gressive dilution either with saline or with FFP (all
P¼1.000 vs baseline). In contrast, peak thrombin gener-
ation and endogenous thrombin potential (ETP) decreased
significantly in saline diluted samples from 429 (29) and
2270 (123) nM at baseline to 249 (27) nM (P,0.001 vs
baseline) and 2060 (78) nM (P¼0.034 vs baseline) after
dilution to 40% and to 136 (23) nM (P,0.001) and 1800
(151) nM (P,0.001) after dilution to 15% of baseline.
After dilution with FFP to 40% and 15% of baseline, peak
thrombin generation and ETP did not change significantly
compared with baseline except that peak thrombin level
was slightly reduced to 382 (22) nM after dilution to 15%
(P¼0.025 vs baseline). Figure 2 shows representative
thrombin generation curves from the same volunteer in the
in vitro model of dilution.
In plasma samples from OPCAB patients, lag time was
4.0 (1.6) min before surgery and 4.9 (2.8) min after
surgery (P¼0.899). Peak thrombin generation decreased
from 427 (63) to 264 (91) nM (P¼0.001), whereas ETP
decreased non-significantly from 2580 (732) to 2100 (715)
nM (P¼0.160).
Thromboelastometry
For the in vitro model of dilution, CT, angle, and MCF
values are shown in Table 3. CT was prolonged and angle
decreased after dilution with saline, whereas these par-
ameters were not significantly different from baseline after
dilution with FFP. MCF was reduced with any dilution,
but MCF values were significantly higher after dilution
with FFP compared with dilution with saline (P,0.001).
Addition of fibrinogen after dilution with saline improved
CT, angle, and MCF (all P,0.001) and made these values
similar to dilution to 15% with FFP (all P0.915).
Figure 3 shows LOT and LT as assessed by thromboelasto-
metry. LOT and LT values after dilution with FFP were
significantly longer compared with the corresponding
dilution with saline (all P,0.001). Addition of fibrinogen
did not significantly improve resistance against fibrinolysis
(P¼1.000 vs both dilution with saline).
Table 4 shows the findings in the OPCAB patients. In
agreement with our in vitro dilution model, angle and
MCF decreased by 8% and 13%, respectively, after
surgery, whereas CT increased by about 1.4-fold. Further,
LOT and LT decreased by about 45%. In the presence of
cytochalasin D, we found a decrease in MCF of 33%, and
decreases of LOT and LT of about 40%.
Discussion
We present the in vitro evidence that FFP administered
with intention to replace acute blood loss confers better
procoagulant and antifibrinolytic activity compared with
treatment with saline or fibrinogen concentrate. Further,
we demonstrate that haemodilution of endogenous antifi-
brinolytic factors is causally related to increased fibrinoly-
tic tendency using both in vitro and in vivo models.
Table 2 In vivo dilution in patients undergoing off-pump coronary artery
bypass (OPCAB) surgery. Data are mean (SD); per cent change relative to
preoperative value. P-values were obtained by paired t-test. PT, prothrombin
time; INR, international normalized ratio; aPTT, activated partial
thromboplastin time; TAFI, tissue-activatable fibrinolysis inhibitor
Preoperative Postoperative P-value
Haemoglobin (g litre21) 134 (18) 91 (22); 232% 0.003
Haematocrit (%) 36.2 (4.5) 24.6 (6.6); 232% 0.002
Platelet (109 litre21) 203 (81) 131 (66); 236% ,0.001
PT (s) 12.1 (1.2) 17.7 (5.0); þ46% 0.010
INR 0.87 (0.11) 1.41 (0.5); þ62% 0.013
aPTT (s) 34.7 (5.8) 43.6 (12.3); þ26% 0.064
Fibrinogen (g litre21) 4.5 (1.3) 2.6 (0.9); 243% ,0.001
Prothrombin (%) 104 (13) 60 (15); 242% 0.001
Antithrombin (%) 98 (8) 61 (10); 238% ,0.001
Plasminogen (%) 101 (18) 61 (15); 240% ,0.001
a2-Antiplasmin (%) 90 (12) 51 (13); 243% ,0.001
TAFI (mg ml21) 9.7 (2.0) 5.8 (1.6); 240% ,0.001
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Fig 2 Representative thrombin generation curve in the PPP of a healthy
volunteer after in vitro dilution: thrombin generation curves cannot be
differentiated to baseline after dilution with FFP to 40% and 15%,
whereas peak thrombin generation decreases dilution-dependently due to
reduced concentration of procoagulant clotting factor. After dilution with
saline, thrombin activity is sustained longer due to reduced antithrombin
activity.
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Coagulopathy after major trauma and surgery has mul-
tiple aetiologies including the loss (haemorrhage) and con-
sumption of coagulation factors and platelets,
haemodilution by fluid replacement, hypothermia, acido-
sis, and disseminated intravascular coagulation (DIC), that
is, excess procoagulant and fibrinolytic activity.14 15
Fibrinolysis is a normal physiological response necessary
to dissolve excess fibrin that is formed within blood
vessels, but re-bleeding may result from the premature
breakdown of fibrin at the injury site.14 Normally, several
physiological mechanisms protect fibrin (clot) against
fibrinolytic enzymes. Plasma concentration of a2-
antiplasmin is relatively high (70 mg ml21, 1 mM), and
this plasmin inhibitor is rapidly cross-linked to fibrin a
chains by thrombin-activated FXIIIa.16 Congenital a2-
antiplasmin deficiency is thus known to cause severe
bleeding tendency due to increased susceptibility to fibri-
nolysis.17 Thrombin is also involved in the activation of
TAFI zymogen (5 mg ml21, 75 nM). Activated TAFI
cleaves carboxy-terminal lysine residues from the fibrin,
and prevents the binding of plasminogen.18 Although
plasma concentration of PAI-1 is low (0.01 mg ml21, 200
pM), platelets release PAI-1 from their a-granules upon
activation, rendering platelet-rich thrombi resistant to fibri-
nolysis.19 20 Conversely, tPA can be released from the
endothelium during acute stress in response to catechol-
amines, thrombin, vasopressin, and other humoral
factors.21 22 Thus, fibrinolytic pathway is relatively well
preserved during haemodilution in conjunction with high
baseline levels of plasminogen (200 mg ml21, 2 mM).
Indeed, increased tPA-induced fibrinolysis was readily
observed on thromboelastometry (Fig. 3) after WB was
diluted to 40% of baseline with normal saline leading to
mild thrombocytopenia (Table 1). In the similar dilution
with FFP, clot stability against fibrinolysis was maintained
until the level of dilution was increased to 15% with FFP
leading to severe thrombocytopenia (platelet count
,40109 litre21, Table 1). Endogenous thrombin gener-
ation did not change after dilution with FFP, but was sub-
stantially affected after dilution with saline. However, the
decrease in peak thrombin was less than expected, that is,
only about 60% of baseline in the dilution to 40% of base-
line and about 33% after dilution to 15% of baseline. This
is in contrast to grossly prolonged PT/aPTT values after
only 40% dilution with saline (Table 1). PT/aPTT pro-
longations described here are in close agreement with
Yuan and colleagues3 who showed that PT/aPTT exceeded
1.5-times normal when coagulation factor levels were 50%
of baseline. Unlike PT/aPTT, the thrombin generation
assay is influenced not only by decreased procoagulant
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Fig 3 Thromboelastometric lysis parameters in the in vitro model of
dilution: LOT and LT were significantly lower after dilution with saline
compared with the corresponding dilution with FFP (*P,0.001). LOT
and LT were comparable with baseline after dilution to 40% with FFP
and decrease only after further dilution. Adding fibrinogen to the sample
diluted with saline to 15% did not significantly increase LOT and LT
(§P¼1.000).
Table 3 Thromboelastometric parameters in the in vitro model of dilution. Values are mean (SD). P-values were obtained by ANOVA followed by Bonferroni’s
post hoc test. *P,0.01 vs baseline; §P,0.01 vs dilution to 15% with saline and fibrinogen. Thromboelastometric data were obtained after stimulation with
EXTEMw in the absence of tPA. FFP, fresh frozen plasma; CT, coagulation time; MCF, maximal clotting firmness
Baseline Dilution to 40% of baseline Dilution to 15% of baseline
With saline With FFP With saline With FFP With saline and fibrinogen
CTEXTEM (s) 58 (7) 90 (15)* 56 (10) 150 (50)*
,§ 58 (9) 71 (11)
AngleEXTEM (8) 70 (5)
§ 57 (7)* 72 (5)§ 33 (4)*,§ 64 (7) 59 (10)*
MCFEXTEM (mm) 57 (4)
§ 39 (4)* 52 (4)§ 23 (2)*,§ 40 (4)* 38 (2)*
Table 4 Thromboelastometric parameters in patients undergoing off-pump
coronary artery bypass (OPCAB) surgery. Data are mean (SD). P-values were
obtained by paired t-test. Thromboelastometric data were obtained either in
the absence (CT, angle, and MCF) or in the presence of tPA (LT and LOT)
after stimulation with EXTEMw or FIBTEMw as specified. CT, coagulation
time; MCF, maximal clotting firmness; LOT, lysis onset time; LT, lysis time
Preoperative Postoperative P-value
CTEXTEM (s) 53 (18) 82 (34) 0.004
AngleEXTEM (8) 76 (3) 70 (6) 0.001
MCFEXTEM (mm) 67 (4) 58 (7) ,0.001
LOTEXTEM (s) 1480 (488) 820 (426) ,0.001
LTEXTEM (s) 2130 (773) 1140 (596) ,0.001
MCFFIBTEM (mm) 21 (4) 14 (5) ,0.001
LOTFIBTEM (s) 1030 (534) 664 (300) 0.005
LTFIBTEM (s) 1540 (901) 901 (376) ,0.001
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factors, but also by lower antithrombin activity;7 thus
thrombin activity is sustained longer in plasma (Table 1).
In this regard, reduced a2-antiplasmin and TAFI levels but
not thrombin generation (to activate TAFI) seem to con-
tribute mainly to fibrinolytic tendency. In parallel with our
in vitro findings, we observed that the WB clot was
more prone to tPA-induced fibrinolysis after major fluid
replacements during the multi-vessel OPCAB procedure
(Tables 2 and 4).
Decreased fibrinogen level, thrombocytopenia, or both
could explain our present in vitro and in vivo findings since
low fibrinogen and low platelet count have been shown to
increase tendency to fibrinolysis.7 8 However, increasing
the fibrinogen concentration did not significantly improve
resistance against fibrinolysis in the in vitro model (Fig. 3).
The interaction between fibrin(ogen) and activated platelets
(via glycoprotein IIb/IIIa) seemed to confer some
antifibrinolytic function because the extent of fibrinolysis
was modestly increased in the presence of cytochalasin D,
an inhibitor of platelet cytoskeletal reorganization
(Table 4). Taken together, restoration of endogenous
antifibrinolytic factors by FFP is presumably the main
mechanism for clot protection in haemodilution-induced
profibrinolytic state.
Clinical management of massive haemorrhage primarily
consists of fluid resuscitation with crystalloids, colloids, or
both in conjunction with red blood cell transfusion to
ensure oxygen delivery.2 5 6 Therefore, we used an in vitro
model which includes haemodilution along with red blood
cell supplementation to simulate clinically used resuscita-
tion schemes.7 The transfusion of haemostatic products
used to be considered secondary to aggressive fluid resus-
citation; however, this approach has been questioned
recently.23 Early intervention using FFP is increasingly
utilized in massive transfusion protocols.9 10 The empirical
ratio of FFP:RBC transfusion of 1:1 seems efficacious in
the retrospective analysis of massively transfused trauma
cases in military and civilian studies.10 24 Survival was
significantly worse with low FFP:RBC transfusion ratio
(e.g. ,1:2) compared with high FFP:RBC ratio. However,
it is difficult to delineate haemostatic mechanisms of FFP
from clinical data which reported normalized PT/INR
because this clotting time does not reflect the full extent
of thrombin generation and fibrin polymerization.25
Further, there are increasing clinical data supporting the
use of fibrinogen concentrate to reduce blood loss after
major surgery.26–28 Therefore, the choice between FFP
and fibrinogen in major haemorrhage remains
controversial.
Our in vitro and in vivo data provide evidence that haemo-
dilution by crystalloids renders clot susceptible to fibrinoly-
sis due to dilution of endogenous antifibrinolytic factors.
However, fibrinolysis may not be detectable unless throm-
boelastometry is performed using tPA to induce fibrinolysis
(Tables 3 and 4). Fibrinogen per se can improve most
thromboelastometric variables;7 however, increased mass of
fibrin is not protected against fibrinolysis unless endogenous
antifibrinolytic elements are restored (Table 1). Levrat and
colleagues29 reported a high incidence of systemic fibrinoly-
sis in trauma patients with higher injury severity scores.
Although these investigators did not provide data on fluid
resuscitation, lower platelet count and coagulation factor
levels suggest that high-risk patients required more crystal-
loids for haemodynamic stabilization, and thus incurred
more haemodilution. Further, haemodilution by colloids
seems to increase susceptibility to fibrinolysis even more
than crystalloids.30 Our findings related to haemodilution
also provide a biochemical basis for the clinical trial
(Crash-2) which investigated the effectiveness of tranexamic
acid in trauma patients.31 32
In cardiac surgery, antifibrinolytic agents are used routi-
nely33 because the extracorporeal circulation is presumed
to induce hyperfibrinolysis via contact activation, and
resultant coagulopathy. Antifibrinolytics have been shown
to decrease blood product usage.33 On the contrary, antifi-
brinolytic therapy is infrequently used in OPCAB surgery
for fear of hypercoagulable state, and thrombotic compli-
cations. Our present data seem to support potential useful-
ness of antifibrinolytic agents in cases of extensive
haemodilution. In agreement, several published double-
blind randomized studies showed that tranexamic acid was
effective in reducing postoperative blood loss and require-
ments for blood-derived products in OPCAB surgery.34
Our data also suggest that FFP supports endogenous
antifibrinolytic activity if given in sufficient amounts as
shown by reduced fibrinolysis on thromboelastometry. In
the case of massive haemorrhage encountered in major
trauma and surgery, anticoagulant (e.g. antithrombin) and
antifibrinolytic factors rapidly decrease below 40% of
baseline,35 and systemic activation of thrombin and
plasmin are likely to follow.14 36 We speculate that early
intervention with FFP before the occurrence of systemic
fibrinolysis might mitigate haemorrhagic tendency
described as early trauma-induced coagulopathy or profi-
brinolytic DIC.10 36
Obviously, there are safety concerns with the routine
use of FFP which limit its therapeutic benefits.11 12 First,
FFP should not be considered as a primary fluid replace-
ment therapy,5 6 and high volume requirement of FFP to
raise factor levels can cause volume overload. Secondly,
there is a potential, although low, risk of viral transmission
with FFP. Such a risk may be further reduced in the future
as more virus-inactivated plasma products become avail-
able.37 The incidence of transfusion-related acute lung
injury has recently decreased after the adaptation of male
only donor policy for FFP.38 However, increased risks for
multi-organ failure and sepsis associated with FFP have
been reported based on the retrospective analysis of trans-
fusion data.12 It is prudent to prospectively evaluate the
potential efficacy and safety of FFP in preventing uncon-
trolled thrombin generation and hyperfibrinolysis in early
trauma-induced coagulopathy.
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In conclusion, we demonstrated a haemodilution-
induced profibrinolytic state in vitro and in vivo. Although
the extent of fibrinolysis occurring in individual cases is
difficult to determine, blood clot is likely more susceptible
to localized fibrinolysis, which can worsen bleeding
related to thrombocytopenia, low fibrinogen, and other
factor deficiencies after major haemorrhage. Early fluid
replacement therapy using FFP might maintain appropriate
levels of clotting factors, and also improve endogenous
antifibrinolytic activity in the absence of exogenous antifi-
brinolytic therapy. Our in vitro finding on haemodilution-
related fibrinolysis was strongly supported by the in vivo
haemodilution data during OPCAB surgery. Further clini-
cal studies are warranted to confirm our findings and to
prospectively investigate the safety and efficacy of early
replacement therapy using FFP vs a combination of fibri-
nogen concentrate and tranexamic acid.
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